Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BBT001

Other · developed by Bambusa Therapeutics

Phase 1/2 Most advanced trial
BBTX Developer
1 Registered trials

What is BBT001?

BBT001 is an investigational agent studied in chronic spontaneous urticaria.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Immunology
Developer
Bambusa Therapeutics (BBTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07717905 Phase 1/2 Chronic Spontaneous Urticaria Recruiting BBTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Spontaneous Urticaria

More from Bambusa Therapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BBTX page.

Follow BBTX, the company behind BBT001

See BBTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BBTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.